Loading clinical trials...
Loading clinical trials...
A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101)
Conditions
Interventions
CX-904
Locations
5
United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Sarah Cannon Research Institute, LLC
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
South Texas Accelerated Research Therapeutics, LLC
San Antonio, Texas, United States
Virginia Cancer Specialist
Fairfax, Virginia, United States
Start Date
May 16, 2022
Primary Completion Date
June 4, 2025
Completion Date
June 4, 2025
Last Updated
July 14, 2025
NCT06898450
NCT06658951
NCT05719558
NCT05101070
NCT06307795
NCT06716138
Lead Sponsor
CytomX Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions